Eli Lilly and Company announced new long-term data on Omvoh (mirikizumab-mrkz) in adults with moderately to severely active Crohn’s disease from the Phase 3 VIVID-2 open-label extension study. Lilly said the results were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) and showed that among patients who achieved specified outcomes at Week 52 in VIVID-1 and continued treatment, 92.4% were in clinical remission and 91.2% were in corticosteroid-free clinical remission at 152 weeks. Lilly also reported additional post hoc analyses presented from the Phase 3 VIVID-1 (Crohn’s disease) and LUCENT-3 (ulcerative colitis) trials describing low rates of IBD-related hospitalizations and surgeries in Omvoh-treated patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191215PR_NEWS_USPR_____DE89989) on February 19, 2026, and is solely responsible for the information contained therein.